GJE client OncoImmunity AS acquired by NEC Corporation

OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate. OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials.

GJE provided OncoImmunity AS with IP-related due diligence support during the acquisition and continues to manage the company’s patent portfolio. The GJE team is led by partner Matt Hoyles.

To read the full press release, please follow this link.

Get in touch

If you are an ambitious business and you expect an IP service provider that can understand and help you achieve your commercial objectives, then we want to work with you. Complete the enquiry form below and one of our specialists will be in touch within one working day. Alternatively you can call us on +44 (0)20 7655 8500. We look forward to hearing from you.